SPIMACO’s Morocco plant approves capital hike to continue project finance

10/11/2020 Argaam

Saudi Pharmaceutical Industries and Medical Appliances Co. (SPIMACO) said in a bourse statement that shareholders of its pharmaceutical plant in Morocco (E-Pharma) approved capital hike from MAD 470 million (SAR 192.7 million) to MAD 582.16 million (SAR 283.7 million).

 

SPIMACO owns a 70.65% stake in the Moroccan affiliate and will contribute to the capital hike through capitalizing the previously granted shareholders’ loan of MAD 47.33  million (SAR 19.4 million), in addition to a cash contribution for the remaining amount that will be determined later by the board of directors. 

 

The capital hike aims at financing the industrial project in Morocco.

 

SPIMACO Morocco is a closed joint stock company engaged in manufacturing, marketing, importing and distributing medicines and pharmaceutical products in Morocco.

Comments {{getCommentCount()}}

Be the first to comment

{{comment.FollowersCount}}
{{comment.CommenterComments}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}} حساب موثّق

{{comment.ElapsedTime}}
{{comment.Replies.length}}
تعديل
loader Train
Report
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.